Terms: = Skin cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
5359 results:
1. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
2. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
Parums DV
Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
[TBL] [Abstract] [Full Text] [Related]
3. Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal cancer Cell Lines Regardless of HPV Status.
Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Anticancer Res; 2024 May; 44(5):1863-1876. PubMed ID: 38677772
[TBL] [Abstract] [Full Text] [Related]
4. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
5. The involvement of RIPK4 in TNF-α-stimulated IL-6 and IL-8 production by melanoma cells.
Madej E; Lisek A; Brożyna AA; Cierniak A; Wronski N; Deptula M; Wardowska A; Wolnicka-Glubisz A
J Cancer Res Clin Oncol; 2024 Apr; 150(4):209. PubMed ID: 38656555
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-targeted therapy with braf-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract] [Full Text] [Related]
7. Overcoming braf and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
8. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract] [Full Text] [Related]
9. Genomic deletions explain the generation of alternative braf isoforms conferring resistance to MAPK inhibitors in melanoma.
Aya F; Lanuza-Gracia P; González-Pérez A; Bonnal S; Mancini E; López-Bigas N; Arance A; Valcárcel J
Cell Rep; 2024 Apr; 43(4):114048. PubMed ID: 38614086
[TBL] [Abstract] [Full Text] [Related]
10. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
[TBL] [Abstract] [Full Text] [Related]
11. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced braf-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
12. Efficiency and tolerance of second-line triple braf inhibitor/MEK inhibitor/anti-PD1 combined therapy in braf mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract] [Full Text] [Related]
13. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
14. braf V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
[No Abstract] [Full Text] [Related]
15. Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract] [Full Text] [Related]
16. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
17. RAF inhibitor re-challenge therapy in braf-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE; Roszik J; Ahmed J; Barretto CMN; Nardo M; Campbell E; Johnson AM; Piha-Paul SA; Oliva ICG; Weathers SP; Cabanillas M; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer; 2024 Mar; 23(1):64. PubMed ID: 38532456
[TBL] [Abstract] [Full Text] [Related]
18. Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care.
Fletcher KA; Johnson DB
Cancer J; 2024 Mar-Apr 01; 30(2):126-131. PubMed ID: 38527267
[TBL] [Abstract] [Full Text] [Related]
19. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic Melanoma Treatment in Special Populations.
Miceli M; Boatwright C; Mehnert JM
Cancer J; 2024 Mar-Apr 01; 30(2):71-78. PubMed ID: 38527259
[TBL] [Abstract] [Full Text] [Related]
[Next]